Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Часто задаваемые вопросы
В каком секторе работает Journey Medical Corp (DERM)?
Journey Medical Corp относится к сектору Здравоохранение.
Какова текущая цена акций Journey Medical Corp (DERM)?
По последним данным, цена акций Journey Medical Corp составляет 4,30 $, предыдущее закрытие — 4,73 $. За последнюю торговую сессию акции Journey Medical Corp снизились на -0,43 $, что соответствует падению на -9,09%.
Выплачивает ли Journey Medical Corp (DERM) дивиденды?
Нет, Journey Medical Corp не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Journey Medical Corp (DERM)?
У компании Journey Medical Corp бета 1.084, что означает, что её волатильность примерно соответствует рыночной.